Resources Repository
-
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Cost-Effectiveness Analysis | Dynamic Transmission | Health Outcomes | Health Systems | Child/Nutrition | State-Transition | Microsimulation | Infectious Diseases | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2019Cost-Effectiveness of Community-Based Childhood Obesity Prevention Interventions in Australia
This study examined the cost-effectiveness of community-based obesity prevention interventions (CBIs) consisting of strategies to …
This study examined the cost-effectiveness of community-based obesity prevention interventions (CBIs) consisting of strategies to promote healthy eating and physical activity for Australian children aged between 5-18 years. A multiple cohort Markov model that simulates diseases associated with overweight and obesity was used to estimate the health benefits, measured as health-adjusted life years (HALYs) and healthcare-related cost offsets from diseases averted due to exposure to the intervention. Health and cost outcomes were estimated over the…
Cost-Effectiveness Analysis | Health Outcomes | Health Systems | Child/Nutrition | State-Transition | Chronic Disease/Risk | Clinical Care | Food/Agriculture | Health/Medicine | Oceania -
ReportPublication 2016DCP3: Reproductive, Maternal, Newborn, and Child Health
This report from the World Bank is the second volume of the Disease Control Priorities, …
This report from the World Bank is the second volume of the Disease Control Priorities, Third Edition (DCP3) series. It focuses primarily on maternal conditions, childhood illnesses, and malnutrition, addressing topics from maternal mortality and morbidity, to acute illness and undernutrition in children under five, to the transition to older childhood and the illnesses that accompany this transition. The Disease Control Priorities Network (DCP) promotes and supports the use of economic evaluation for priority setting…
Cost-Effectiveness Analysis | Health Outcomes | Health Systems | Child/Nutrition | Costing Methods | Evidence Synthesis | Maternal/Reproductive Health | Global Governance | Economics/Finance | Health/Medicine | Global -
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Cost-Effectiveness Analysis | Health Outcomes | Health Systems | Child/Nutrition | Costing Methods | Evidence Synthesis | Benefit-Cost Analysis | Infectious Diseases | Maternal/Reproductive Health | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Policy/Regulation | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Dynamic Transmission | Health Systems | Child/Nutrition | Mathematical Models | Infectious Diseases | Global Governance | Climate/Environment | Economics/Finance | Health/Medicine | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Extended CEA: Diarrhea and Pneumonia in Ethiopia
This chapter examines universal public finance of the prevention and treatment of pneumonia and diarrhea …
This chapter examines universal public finance of the prevention and treatment of pneumonia and diarrhea in Ethiopia, with a focus on children under age five years. This extended cost-effectiveness analysis examines benefits by income quintile so that policy makers can better understand how each package affects different segments of the population and permits the incorporation of financial risk protection in the economic evaluation of health policies - both critical elements of universal health coverage.
Cost-Effectiveness Analysis | Health Outcomes | Health Systems | Child/Nutrition | Priority Setting/Ethics | Infectious Diseases | Social Determinants | Economics/Finance | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2015Extended Cost-Effectiveness Analysis of Treatment and Prevention of Diarrhoea in Ethiopia
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits …
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits due to the treatment and prevention of diarrhoea (i.e., rotavirus vaccination) in Ethiopia. The authors use an economic model to examine the impacts of universal public finance (UPF) of diarrhoeal treatment alone, as opposed to diarrhoeal treatment along with rotavirus vaccination using extended cost-effectiveness analysis (ECEA). The study finds that diarrhoeal treatment paired with rotavirus vaccination is more cost effective…
Cost-Effectiveness Analysis | Health Outcomes | Health Systems | Child/Nutrition | Priority Setting/Ethics | Costing Methods | Infectious Diseases | Social Determinants | Environmental Health | Climate/Environment | Economics/Finance | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2009Cost-Effectiveness of Rotavirus Vaccination in Vietnam
This article reports on a cost-effectiveness analysis of rotavirus vaccination, including varying degrees of severity, …
This article reports on a cost-effectiveness analysis of rotavirus vaccination, including varying degrees of severity, age-dependency of clinical manifestation, and additional features of the disease (e.g., the possibility of reinfection and varying degrees of partial immunity conferred by natural infection). The authors developed a Markov model that reflects key features of rotavirus infection, using the most recent data available at the time of their analysis. They applied the model to the 2004 Vietnamese birth cohort…
Cost-Effectiveness Analysis | Calibration/Validation | Health Systems | Child/Nutrition | Mathematical Models | Infectious Diseases | Health/Medicine | Asia & Pacific -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Cost-Effectiveness Analysis | Calibration/Validation | Health Outcomes | Health Systems | Mathematical Models | Infectious Diseases | Chronic Disease/Risk | Health/Medicine | Global | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific